Scilex Holding (SCLX) Receivables (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Receivables of $19.2 million for Q1 2026, up 80.81% year-over-year from $10.6 million in Q1 2025, and up 60.79% on a QoQ basis from $11.9 million in Q3 2025.
Scilex Holding (SCLX) Receivables (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Receivables for 6 consecutive years, with $19.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 80.81% year-over-year to $19.2 million; the TTM figure through Mar 2026 stood at $19.2 million (up 80.81% YoY), while the FY2024 annual figure was $26.4 million, up 726.31% from the prior year.
- Receivables came in at $19.2 million for Q1 2026 at Scilex Holding, up from $11.9 million in the prior quarter.
- The five-year high for Receivables was $34.6 million in Q4 2023, with the low at $3.2 million in Q2 2023.
- Average Receivables over 5 years is $16.0 million, with a median of $16.8 million recorded in 2025.
- The largest YoY upside for Receivables was 886.88% in 2024 against a maximum downside of 85.74% in 2024.
- Year by year, Receivables stood at $21.2 million in 2022, then jumped by 62.92% to $34.6 million in 2023, then declined by 23.57% to $26.4 million in 2024, then tumbled by 54.84% to $11.9 million in 2025, then soared by 60.79% to $19.2 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $19.2 million, $11.9 million, and $16.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 21.18 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 17.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 12.48 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 19.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.20 Mn |
| Sep 30, 2025 | 11.94 Mn |
| Jun 30, 2025 | 16.77 Mn |
| Mar 31, 2025 | 10.62 Mn |
| Dec 31, 2024 | 26.44 Mn |
| Sep 30, 2024 | 3.20 Mn |
| Jun 30, 2024 | 38.00 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 34.60 Mn |
| Sep 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 22.44 Mn |
| Dec 31, 2022 | 21.24 Mn |
| Dec 31, 2021 | 14.27 Mn |